•
Jun 30, 2020
RAPT Q2 2020 Earnings Report
Reported financial results for the second quarter ended June 30, 2020
Key Takeaways
RAPT Therapeutics reported a net loss of $12.4 million for the second quarter of 2020, compared to a net loss of $10.6 million for the second quarter of 2019. As of June 30, 2020, the company had cash and cash equivalents and marketable securities of $133.0 million.
Net loss for the second quarter of 2020 was $12.4 million.
Research and development expenses for the second quarter of 2020 were $11.0 million.
General and administrative expenses for the second quarter of 2020 were $2.8 million.
Cash and cash equivalents and marketable securities totaled $133.0 million as of June 30, 2020.